Search Results

Dixon Technologies has issued an irrevocable corporate guarantee of 220 million USD on behalf of its subsidiary Padget Electronics in favor of Lenovo Ireland to secure IT hardware component procurement.

An in-depth clinical and market analysis of GLP-1 therapeutics in 2026, examining central brain reward circuit mapping from the University of Virginia, Phase 3 oral small-molecule data for Orforglipron, Retatrutide triple-agonist efficacy, and systemic cardiometabolic benefits.

As professional buyers shift from search engines to AI assistants and LinkedIn for vendor research, B2B pharmaceutical and life science companies are pivoting from traditional keyword rankings to "Search Everywhere" and Generative Engine Optimization (GEO).

Jefferies has revised its debut-quarter US sales estimate for Eli Lilly's oral GLP-1 drug Foundayo (orforglipron) down to $71 million - well below the Wall Street consensus of $130 million and sharply below its own prior estimate of $85 million. With weekly prescriptions hovering around 20,000 and Novo Nordisk's oral Wegovy outpacing it on trajectory, the first oral non-peptide GLP-1 for obesity is generating a very different story than the hype suggested.

Global research pipelines and venture capital inflows are concentrating in targeted cancer therapy with ADCs and next-generation cardiometabolic GLP-1 oral weight-loss compounds.

Ireland’s status as a corporate hub for global pharmaceutical multinationals has created a unique statistical paradox-masking true economic health and dragging the EU’s GDP into negative territory in the first quarter of 2026. We examine the tax structures, tariff-hedging inventory builds, and supply chain strategies driving this anomaly.

Recent reports suggest Irish pharma workers are the highest paid in Europe, but a deeper dive reveals a more complex reality. We analyze compensation packages, tax regimes, and cost of living across Europe’s top pharmaceutical hubs.

With the obesity market projected to exceed $130 billion by 2034, we analyze the top 10 pharmaceutical companies vying for dominance. Explore our comprehensive Power Rankings assessing pipeline depth, clinical differentiation, and commercial infrastructure.

Novo Nordisk commits €432 million to upgrade its Athlone facility, expanding manufacturing capacity for oral GLP-1 weight-loss and diabetes treatments.

Middle East air route disruptions are raising costs and delaying Ireland’s pharma exports, impacting global medicine supply chains.